CN1709404A - 一种防治中风疾病的中成药及其生产方法、用途 - Google Patents
一种防治中风疾病的中成药及其生产方法、用途 Download PDFInfo
- Publication number
- CN1709404A CN1709404A CN 200510050192 CN200510050192A CN1709404A CN 1709404 A CN1709404 A CN 1709404A CN 200510050192 CN200510050192 CN 200510050192 CN 200510050192 A CN200510050192 A CN 200510050192A CN 1709404 A CN1709404 A CN 1709404A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese patent
- patent medicine
- preventing
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 201000010099 disease Diseases 0.000 title description 16
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 41
- 239000008280 blood Substances 0.000 claims abstract description 41
- 210000004369 blood Anatomy 0.000 claims abstract description 41
- 208000006011 Stroke Diseases 0.000 claims abstract description 40
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 19
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 19
- 230000007812 deficiency Effects 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 241000241550 Cyathula Species 0.000 claims abstract description 6
- 241000628997 Flos Species 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 12
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000005457 optimization Methods 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 241000411851 herbal medicine Species 0.000 claims description 4
- 239000010413 mother solution Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000011812 mixed powder Substances 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 241000736199 Paeonia Species 0.000 abstract description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 abstract 1
- 241000208809 Carthamus Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 241000207925 Leonurus Species 0.000 abstract 1
- 241000244355 Ligusticum Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 23
- 210000002105 tongue Anatomy 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 239000008727 tongluo Substances 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004159 blood analysis Methods 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000009592 kidney function test Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 238000013077 scoring method Methods 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical group Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 例数 | 基本治愈 | 显效 | 有效 | 无效 | 总有效率 | 愈显率 |
N % | N % | N % | N % | % | % | ||
治疗组对照组 | 300110 | 25 8.339 8.18 | 128 42.6728 25.45 | 113 37.6745 40.91 | 34 11.3328 25.45 | 88.6774.54 | 51.0033.64 |
组别 | 例数 | 疗前 | 疗后 | 组内比较 | 组间比较 |
t p | t p | ||||
治疗组对照组 | 300110 | 13.83±6.0912.65±5.57 | 6.53±5.776.3±5.4 | 16.26<0.018.58<0.01 | 2.91<0.01 |
组别 | 例数 | 疗前 | 疗后 | 组内比较 | 组间比较 |
t p | t p | ||||
治疗组对照组 | 300110 | 10.49±4.879.87±4.48 | 4.22±5.204.45±4.62 | 15.29<0.018.89<0.01 | 1.35>0.05 |
组别 | 例数 | 舌质 | 舌苔 | 脉象 | |
暗淡 瘀斑 | 薄白 白腻 | 沉细 细缓 细涩 | |||
治疗组 | 300 | 疗前疗后 | 166 134204 96 | 198 102241 59 | 117 142 4145 137 18 |
对照组 | 110 | 疗前疗后 | 74367931 | 79 3189 21 | 35 57 1541 55 14 |
病情例数 | 愈 | 显 | 有 | 无 | 总有效率 | 愈显率 |
N % | N % | N % | N % | % | % | |
217749 | 21 9.684 5.410 0 | 100 46.0827 36.491 11.11 | 77 35.4831 41.895 55.56 | 19 8.7612 16.223 33.33 | 91.2483.7866.67 | 55.7641.8911.11 |
病情例数 | 例数 | 愈 | 显 | 有 | 无 | 总有效率 | 愈显率 |
N % | N % | N % | N % | % | % | ||
≤3天4-7天8-15天 | 1369965 | 16 11.768 8.081 1.54 | 68 50.0037 37.3723 35.38 | 42 30.8843 43.4328 43.08 | 10 7.3511 11.1113 20.00 | 92.5588.8880.00 | 61.7645.4536.92 |
项目 | 例数 | 疗前 | 疗后 | 组内 | |
全血比粘度 | 高切值 | 110 | 6.58±1.32 | 5.76±1.35 | 4.56<0.05 |
低切值 | 110 | 10.21±2.28 | 9.65±2.10 | 1.86<0.05 | |
血浆比粘度 | 110 | 1.82±0.2 | 0.18±0.08 | 1.45>0.05 | |
红细胞压积 | 110 | 48.16±5.1 | 47.10±3.65 | 1.55>0.05 |
项目 | 例数 | 疗前 | 疗后 | 组内 |
胆固醇 | 187 | 5.11±1.41 | 5.18±1.24 | 0.51>0.05 |
甘油三脂 | 187 | 1.61±0.63 | 1.52±0.78 | 0.06>0.05 |
高密脂 | 187 | 1.15±0.31 | 1.13±0.21 | 0.76>0.05 |
项目 | 例数 | 疗前 | 疗后 | 组内 |
转氨酶 | 103 | 15.61±11.24 | 14.31±10.21 | 0.56>0.05 |
总蛋白 | 103 | 68.64±5.15 | 69.15±4.14 | 0.78>0.05 |
胆红素 | 103 | 10.95±±2.11 | 11.01±2.15 | 0.2.0>0.05 |
项目 | 例数 | 疗前 | 疗后 | 组内 |
尿素氮 | 117 | 5.15±1.32 | 5.05±1.10 | 0.63>0.05 |
项目 | 例数 | 疗前 | 疗后 | 组内 |
收缩压 | 186 | 138.75±47.56 | 133.92±46.71 | 0.986>0.05 |
舒张压 | 186 | 86.27±15.12 | 84.98±14.83 | 0.83>0.05 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100501928A CN1318083C (zh) | 2005-06-21 | 2005-06-21 | 一种防治中风疾病的中成药及其生产方法、用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100501928A CN1318083C (zh) | 2005-06-21 | 2005-06-21 | 一种防治中风疾病的中成药及其生产方法、用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1709404A true CN1709404A (zh) | 2005-12-21 |
CN1318083C CN1318083C (zh) | 2007-05-30 |
Family
ID=35705736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100501928A Active CN1318083C (zh) | 2005-06-21 | 2005-06-21 | 一种防治中风疾病的中成药及其生产方法、用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1318083C (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104225122A (zh) * | 2014-09-17 | 2014-12-24 | 韩祖成 | 中风病刚柔相济综合康复方法 |
CN104998129A (zh) * | 2015-08-25 | 2015-10-28 | 梁作勇 | 一种用于蛛网膜下腔出血的中药制剂及其制备方法 |
CN105853375A (zh) * | 2016-05-27 | 2016-08-17 | 南京柯菲平盛辉制药有限公司 | 一种干法制备脑脉利颗粒的方法 |
CN106265079A (zh) * | 2015-05-27 | 2017-01-04 | 江苏柯菲平医药股份有限公司 | 一种防治中风疾病的中成药颗粒干燥方法 |
CN106668327A (zh) * | 2017-03-09 | 2017-05-17 | 马新军 | 一种治疗脑神经及脑血管疾病的药物及制备方法 |
CN109331100A (zh) * | 2018-09-28 | 2019-02-15 | 史利 | 一种用于治疗脑梗后遗症的中药组合物 |
CN117618396A (zh) * | 2023-12-27 | 2024-03-01 | 南京柯菲平盛辉制药有限公司 | 一种脑脉利颗粒及其制备方法、以及对神经保护作用的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1059123C (zh) * | 1998-10-22 | 2000-12-06 | 张继旭 | 一种治疗脑中风的药物 |
-
2005
- 2005-06-21 CN CNB2005100501928A patent/CN1318083C/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104225122A (zh) * | 2014-09-17 | 2014-12-24 | 韩祖成 | 中风病刚柔相济综合康复方法 |
CN106265079A (zh) * | 2015-05-27 | 2017-01-04 | 江苏柯菲平医药股份有限公司 | 一种防治中风疾病的中成药颗粒干燥方法 |
CN104998129A (zh) * | 2015-08-25 | 2015-10-28 | 梁作勇 | 一种用于蛛网膜下腔出血的中药制剂及其制备方法 |
CN105853375A (zh) * | 2016-05-27 | 2016-08-17 | 南京柯菲平盛辉制药有限公司 | 一种干法制备脑脉利颗粒的方法 |
CN106668327A (zh) * | 2017-03-09 | 2017-05-17 | 马新军 | 一种治疗脑神经及脑血管疾病的药物及制备方法 |
CN109331100A (zh) * | 2018-09-28 | 2019-02-15 | 史利 | 一种用于治疗脑梗后遗症的中药组合物 |
CN117618396A (zh) * | 2023-12-27 | 2024-03-01 | 南京柯菲平盛辉制药有限公司 | 一种脑脉利颗粒及其制备方法、以及对神经保护作用的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1318083C (zh) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1709404A (zh) | 一种防治中风疾病的中成药及其生产方法、用途 | |
CN1709445A (zh) | 一种主治急慢性扭挫伤、风湿、类风湿疾病的藏药药物及其制备方法 | |
CN106138668B (zh) | 一种治疗慢性阻塞性肺疾病的中药组合物及其制备方法 | |
CN1726929A (zh) | 一种治疗糖尿病的药物组合物 | |
CN1927331A (zh) | 一种治疗慢性心力衰竭的中药制剂 | |
CN1255154C (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1232285C (zh) | 一种治疗颈椎病的中药及其制备方法 | |
CN1679679A (zh) | 一种中药组合物及其制备方法 | |
CN115837065A (zh) | 一种中药组合物及其用途 | |
CN1857495A (zh) | 一种治疗痛证的中药复方制剂及其制备方法 | |
CN1820770A (zh) | 一种治疗中风的中药组合物及其制备方法 | |
CN1990033A (zh) | 一种治疗高血压、血稠、动脉硬化的药物 | |
CN103655801B (zh) | 一种治疗贫血的药物 | |
CN1520862A (zh) | 一种用于治疗中风和胸痹的中成药 | |
CN1232283C (zh) | 治疗冠心病心绞痛的中药 | |
CN1233361C (zh) | 一种治疗心血管疾病的中药组合物 | |
CN1899581A (zh) | 用于气滞寒凝胃痛的药物组合物及其制备方法和用途 | |
CN1227023C (zh) | 一种治疗冠心病心绞痛的药物及其制备方法 | |
CN1840101A (zh) | 具有祛风除湿、通经络、散寒止痛功能的中药及制备工艺 | |
CN1276764C (zh) | 一种中药组合物在制备治疗缺铁性贫血药物中的应用 | |
CN1650895A (zh) | 从天然植物复方制剂中提取增强记忆制品药物的方法 | |
CN1541691A (zh) | 治疗急性黄疸肝炎的中药及其制备方法 | |
CN1593493A (zh) | 辅康艾制剂及其制备方法 | |
CN1709318A (zh) | 一种治疗中风病的中药口服液 | |
CN1253188C (zh) | 一种治疗高血压的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEFEI HEYUAN DRUG INDUSTRY CO., LTD. Free format text: FORMER OWNER: HANGZHOU XINFU PHARMACEUTICAL CO., LTD., ZHEJIANG Effective date: 20110718 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 311305 LIN'AN ECONOMIC DEVELOPMENT ZONE, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 230031 NO. 180, GANQUAN ROAD, HEFEI CITY, ANHUI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110718 Address after: 230031 No. 180 Ganquan Road, Anhui, Hefei Patentee after: Hefei Heyuan Drug Industry Co., Ltd. Address before: 311305 Ling'an Economic Development Zone, Zhejiang, Hangzhou Patentee before: Hangzhou Xinfu Pharmaceutical Co., Ltd., Zhejiang |
|
ASS | Succession or assignment of patent right |
Owner name: NANJING KEFEIPING SHENGHUI PHARMACEUTICAL CO., LTD Free format text: FORMER OWNER: HEFEI HEYUAN DRUG INDUSTRY CO., LTD. Effective date: 20141113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 230031 HEFEI, ANHUI PROVINCE TO: 211200 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141113 Address after: 211200 Lishui economic and Technological Development Zone (South District), Jiangsu, Nanjing Patentee after: NANJING CAREFREE SHENGHUI PHARMACEUTICAL CO., LTD. Address before: 230031 No. 180 Ganquan Road, Anhui, Hefei Patentee before: Hefei Heyuan Drug Industry Co., Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160111 Address after: Xuanwu District of Nanjing City, Jiangsu province 210016 former banshanyuan No. 12 Building 1 layer 1 Patentee after: JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD. Address before: 211200 Lishui economic and Technological Development Zone (South District), Jiangsu, Nanjing Patentee before: NANJING CAREFREE SHENGHUI PHARMACEUTICAL CO., LTD. |
|
DD01 | Delivery of document by public notice |
Addressee: Ge Hui Document name: Notification of Passing Examination on Formalities |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20051221 Assignee: NANJING CAREFREE SHENGHUI PHARMACEUTICAL CO., LTD. Assignor: JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD. Contract record no.: 2016320000154 Denomination of invention: Chinese patent medicine for preventing and treating apoplexia disease, and its production method and use Granted publication date: 20070530 License type: Exclusive License Record date: 20160617 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: NANJING CAREFREE SHENGHUI PHARMACEUTICAL CO., LTD. Assignor: JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD. Contract record no.: 2016320000154 Date of cancellation: 20161213 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20051221 Assignee: NANJING CAREFREE SHENGHUI PHARMACEUTICAL CO., LTD. Assignor: JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD. Contract record no.: 2016320000242 Denomination of invention: Chinese patent medicine for preventing and treating apoplexia disease, and its production method and use Granted publication date: 20070530 License type: Exclusive License Record date: 20161228 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180809 Address after: 211200 No. 28 Shui Bao Road, Lishui economic and Technological Development Zone (Southern District), Nanjing, Jiangsu Patentee after: NANJING CAREFREE SHENGHUI PHARMACEUTICAL CO., LTD. Address before: 210016 Nanjing, Jiangsu, Xuanwu District, the first half hill 12, 1, 1 stories. Patentee before: JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD. |